TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Effect of Cognitive Game Based Treadmill Exercise Program in Parkinson Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age range 55-70~* Diagnosed with PD according to UK brain bank criteria,~* PD stage 1-3 on Hoehn and Yahr scale,~* On stable medications for PD from past 3months,~* Able to walk 50m independently,~* Montreal Cognitive Assessment( MoCA) score of more than 21(Non-Dementia PD).~Exclusion Criteria:~* Any other neurodegenerative condition,~* Any orthopedic or cardiovascular impairment limiting independent walking for a minimum of 10 minutes.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Intervention Group: Participants in the intervention group will receive DT TT with GTP. GTP consists of standard treadmill nested with a pressure mapping system and an interactive computer game based sub-station in front of the treadmill. A miniature motion mouse with inbuilt sensors that enables real-time movements to be translated in computer sub-station by standard USB will be used. This miniature mouse will be secured to a helmet that participants will wear while walking on the treadmill to interact with computer sub-station. Participants will be expected to play commercial computer games while standing on compliant surface or walking on the treadmill. The motion mouse will help participants to control computer games hand free.
- Control Group (Type: ACTIVE_COMPARATOR): Control group: Participants in the control group will undergo a mixture of current gait training programs available for people with Parkinson Disease. The protocol will be:

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary squamous cell carcinoma of head and neck, after tumor excision and neck dissection, pathology has confirmed three or more of the following adverse prognostic factors, including:~  1. Marginale surgery but a safe distance from the residual tumor ≦ 4mm.~ 2. The tumor is located in the hard palate or the retromolar region.~ 3. Poorly differentiated cell type.~ 4. Tumor invasion to the nerve.~ 5. Tumor invasion to lymphatic vessels.~ 6. Tumor invasion to the small blood vessels.~ 7. Tumor invasion to the bone.~ 8. Tumor invasion to the skin.~ 9. Depth of tumor invasion ≧ 10mm.~ 10. Occurred in single lymph node metastasis.~Exclusion Criteria:~* No or presence of adverse prognostic factor but less than 2.~* Presence of either one conditions listed here: positive resection margin, resection margin negative but less than 1 mm, pathologic N2 or N2, or presence of nodal metastasis with extracapsular spreading.~* ECOG performance status \> 2.~* Previous cancer history (except basal cell or squamous cell skin cancer) or other synchronous malignant disease.~* Women during pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- concurrent chemoradiation (Type: EXPERIMENTAL): patients who has 3 or more minor risk factors of recurrence, and will receive postoperative chemoradiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Readmissions in High-Risk Ostomates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo surgery that will result in the creation of an ileostomy.~* Agreed to receive home healthcare.~* At least 18 years of age.~* Speaks English.~* Has access to telephone.~* Able to understand and willing to sign an IRB-approved written informed consent document.~Exclusion Criteria:~-Unwilling or unable to receive home health care.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: Standard of care (Type: ACTIVE_COMPARATOR): * Standard of care pre-operative education~* Standard of care home health visits~* Standard of care follow-up post-operative visits with surgeon and CWOCN~* At 30-days post hospital discharge, the participant will:~  * See the physician~ * Turn in Patient Data Collection Form~ * Turn in Healthcare Utilization Form~ * Complete The City of Hope QOL Survey for Ostomy Patients~ * Ostomy assessment with a CWOCN, including photo of ostomy site
- Group B: Phone call (Type: EXPERIMENTAL): * Standard of care pre-operative education~* Standard of care home health visits~* Standard of care follow-up post-operative visits with surgeon and CWOCN~* Telephone call 48-72 hours post-discharge from CWOCN/PA to evaluate tolerability to foods/fluids, activity level, screen for red-flags, review/assess for medication, reviewing pouching of ostomy, review patient's ability to obtain supplies, provide continued education, discuss proper use of durable medical equipment/frequency of pouch changes, and complete Patient Assessment Form.~* At 30-days post hospital discharge, the participant will:~  * See the physician~ * Turn in Patient Data Collection Form~ * Turn in Healthcare Utilization Form~ * Complete The City of Hope QOL Survey for Ostomy Patients~ * Ostomy assessment with a CWOCN, including photo of ostomy site

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed mild COVID-19 (NEWS scoring system 0-4)~Exclusion Criteria:~* unable to take oral medication~* pregnancy or breast feeding~* immunocompromised patients~* creatinine clearance (CCL) \< 30 mL/min~* aspartate transaminase (AST) or alanine transaminase (ALT) \> 5 times Upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Lopinavir/ritonavir (Type: EXPERIMENTAL): Lopinavir/ritonavir 200mg/100mg 2 tablets by mouth, every 12 hours for 7-10 days
- Hydroxychloroquine (Type: ACTIVE_COMPARATOR): Hydroxychloroquine 400mg by mouth, every 24 hours for 7-10 days
- Control (Type: NO_INTERVENTION): No lopinavir/ritonavir and hydroxychloroquine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have signed consent for LAB03-0383~2. Pathologic documentation of NSCLC~3. Stage IIIA and IIIB (T4 satellite nodules or invasion into T4 structures but no malignant effusion) with all patients requiring mediastinoscopy positive N2, potentially resectable disease. N3 disease is excluded.~4. Measurable disease~5. Zubrod performance status of 0 or 1~6. Calculated post-resectional FEV1 of \> 40%~7. WBC\>4000/l, ANC\>1500/l, platelets \> 100,000/l~8. Serum creatinine \< 1.5 ULN or calculated creatinine \> 50 cc/min~9. Total serum bilirubin \<1.5 x ULN or SGPT or SGOT \< 2 X ULN~10. The following must be completed within 28 days of registration: CT scan of the chest and upper abdomen to include the adrenals. Mediastinoscopy to document ipsilateral nodal involvement and exclude N3 disease Blood tests, and pulmonary function tests The following must be completed within 2 months of registration: Pet scan If a CT PET is done more than 28 days, only the CT needs to be repeated and a bone scan to rule out bone metastases~Exclusion Criteria:~1. No prior chemotherapy or radiation for NSCLC~2. No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the patient has been disease-free for at least five years. If patient is suspected or known to have basal or squamous skin cancer, this maybe treated after induction chemotherapy is completed at the time of thoracotomy.~3. No post-obstructive pneumonia or other serious infection or other serious underlying medical condition that would impair ability of patient to receive protocol treatment, including prior allergic reactions to drugs containing cremophor.~4. Pregnant or nursing women may not participate

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy + Tarceva (Type: ACTIVE_COMPARATOR): None
- Chemotherapy Alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Blood Loss With a Point Of Care Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years~* Patient in antiplatelet monotherapy (aspirin or clopidogrel) or dual therapy (aspirin + clopidogrel / prasugrel / ticagrelor) in the context of secondary prevention after:~  * acute coronary syndrome~ * and / or intracoronary stenting~* Planned or urgent hip (gamma nail, total prosthesis or through DHS) or knee arthroplasty~* Informed consent of the participant~* Patient receiving a social security scheme or entitled~Exclusion Criteria:~* Polytrauma~* Anemia \<9g/dL~* Indication for oral anticoagulation~* Pelvic fracture justifying complex surgery~* Ongoing or recent major bleeding or recent major surgery (\< 3 weeks)~* Liver failure~* Thrombopenia \<80 000/µl~* Lack of health insurance~* Mental disability~* Participation to any other research protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Planned hip or knee arthroplasty (Type: None): Patients with planned hip or knee arthroplasty
- urgent hip or knee arthroplasty (Type: None): Patients with hip or knee arthroplasty in emergency.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients from 7 to less than 18 years~* Out patients~* Primary diagnosis of ASD as per Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria~* Criteria met for ASD on Autism Diagnostic Observation Schedule (ADOS-2) and Autism Diagnosis Interview Revised (ADI-R)~* CGI (Clinical Global Impression) - Severity rating Score ≥ 4~* Childhood Autism Rating Scale second edition (CARS2-ST or HF) total raw score ≥ 34~* Social responsiveness Scale second edition total score (SRS-2 T-Score) ≥ 66~* Absence of known monogenic syndrome (Fragile X, Rett syndrome ...)~* Absence of any clinically significant abnormality likely to interfere with the conduct of the study according to the judgment of the investigator~Exclusion Criteria:~* Patients not able to follow the study assessments defined by the protocol, with the exception of self-rating questionnaires which will be assessed by parent/legal representative/caregiver for those patients unable to complete them~* Patients having a high suicidal risk according to the investigator judgement~* Chronic renal dysfunction~* Chronic cardiac dysfunction~* Patient with unstable psychotherapy, behavioural, cognitive or cognitive-behavioural therapy~* Severe electrolyte imbalance that is likely to interfere with the study conduct or evaluation

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Bumetanide/S95008 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Key Eligibility Criteria:~* Must have had HIV-associated neuropathy for at least 2 months, with moderate to severe pain in both feet.~* Must not have significant pain in feet due to other causes (for example, arthritis).~* Must have intact skin at the treatment area.~* Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (12 weeks).~* Must not use topical pain medications for HIV-associated neuropathy.~* Must be able to comply with study requirements such as completing daily pain diary and attending study visits.~* Must be at least 18 years old, not pregnant, and be able to take care of self independently, with only occasional assistance if needed.~* No significant medical problems of the heart, kidneys, liver or lungs, or cancer.~* No history or current problem with substance abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* With confirmed diagnosis of Crohn's disease~* Adalimumab-naïve patient (a patient having received an anti-TNF other than adalimumab may enter the study)~* Starting a treatment with adalimumab~* Guardian capable of and willing to grant authorization for use/disclosure of data collected and patient able to comply with the requirements of the study protocol.~Exclusion Criteria:~* Participants with a history of treatment with adalimumab~* Participants enrolled in a concomitant interventional clinical trial.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Pediatric participants receiving adalimumab (Type: None): Pediatric participants receiving adalimumab for CD in real-life conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MODULA Modul 7 VRR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with CRT system with the VRR algorithm~* Patients with permanent atrial fibrillation~* Occasional conducted atrial fibrillation resulting in ventricular rates \> 70 beats per minute (bpm)~* QRS complex \> 120 ms~Exclusion Criteria:~* Patients with third degree atrioventricular (AV) block

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ventricular Rate Regulation feature ON (Type: EXPERIMENTAL): None
- Ventricular Rate Regulation feature OFF (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVA~* Planned treatment with radical radiotherapy with or without concurrent cisplatin chemotherapy.~* Age ≥ 18 years.~Exclusion Criteria:~* Any anticancer treatment for their cervical cancer.~* Eastern Cooperative Oncology Group (ECOG) performance status \> 2~* Other cervical cancer tumor histologies (e.g. small cell, serous)~* Contraindications to 18FDG PET-CT~* Inability to lie supine for 18FDG PET-CT~* Contraindication to radiotherapy (e.g. severe Crohn's disease)~* History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 5 years.~* Known pregnancy or lactating

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyperpolarized Pyruvate (13C) Injection (Type: ACTIVE_COMPARATOR): Participants will be injected with the study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43 ml/kg and will have their cervix imaged using MRI.
- 18F-FDG (Type: ACTIVE_COMPARATOR): Participants will be injected with the study drug 18F-FDG at a dose of 5 MBq/kg to a a maximum of 500 MBq (megabecquerel) and will have their cervix imaged using PET-CT imaging.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of GRASP Medical Device to Improve Arm Coordination After Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Damage to the following areas of the brain, all of which may be involved in coordination of reach to grasp confirmed by CT scan: parietal, cerebellar, internal capsule and basal ganglia,~2. A score of 6 or more on the arm section of the Rivermead Motor Assessment (able to reach and pick up a tennis ball and release on thigh),~3. Time between start of hand opening and start of hand transport \> 60 ms (measured with GRASP).~Exclusion Criteria:~1. Cognitive dysfunction which prevents understanding of the task,~2. Severe concurrent medical problems that prevent repetitive reaching (including shoulder pain),~3. A diagnosis of Parkinson's disease, or~4. Lack of informed consent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nursing Therapeutics Education and Heart Failure (HF): a Study Protocol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients affected by heart failure following elective hospitalization during which an ICD was implanted on an arrhythmic and/or ischemic basis.~* Patients who have given written consent for the research.~Exclusion Criteria:~* Patients with syndromes and diseases that compromise their understanding of information, learning and all cognitive activities in general.~* Minors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nursing therapeutics education (Type: EXPERIMENTAL): People who are educated by the nurse (Behavioral intervention: Nursing therapeutics education) and follow all the program (12 months)
- Non NET (Type: NO_INTERVENTION): People who receive basic information without follow the educational program but clinically controlled

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility